Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: A randomized trial

Annals of Internal Medicine

Volumn 159, Issue 11, 2013, Pages 729-738

  Liu, Chen Hua ^a   Huang, Chung Feng ^b   Liu, Chun Jen ^a   Dai, Chia Yen ^b   Liang, Cheng Chao ^c   Huang, Jee Fu ^b   Hung, Peir Haur ^d   Tsai, Hung Bin ^e   Tsai, Meng Kun ^a   Chen, Shih I ^a   Lin, Jou Wei ^a   Yang, Sheng Shun ^f   Su, Tung Hung ^a   Yang, Hung Chih ^a   Chen, Pei Jer ^a   Chen, Ding Shinn ^a   Chuang, Wan Long ^b   Yu, Ming Lung ^b   Kao, Jia Horng ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^d CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^e BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^f TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA2A; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTIVIRAL THERAPY; ARTICLE; ATTRIBUTABLE RISK; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEPRESSION; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENAL ULCER BLEEDING; ERYTHROCYTE TRANSFUSION; FAINTNESS; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROENTERITIS; GENOTYPE; HAIR LOSS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INJECTION SITE REACTION; INSOMNIA; IRRITABILITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALMONELLOSIS; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TAIWAN; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84984584179     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-159-11-201312030-00005     Document Type: Article

References (47)

1. Berenguer M. Treatment of chronic hepatitis C in hemodialysis patients. Hepatology. 2008;48:1690-9. [PMID: 18972442]
2. Martin P, Fabrizi F. Hepatitis C virus and kidney disease. J Hepatol. 2008;49:613-24. [PMID: 18662838]
3. Liu CH, Kao JH. Treatment of hepatitis C virus infection in patients with end-stage renal disease. J Gastroenterol Hepatol. 2011;26:228-39. [PMID: 21261711]
4. Fabrizi F, Messa P, Martin P. Transmission of hepatitis C virus infection in hemodialysis: current concepts. Int J Artif Organs. 2008;31:1004-16. [PMID: 19115192]
5. Liu CH, Liang CC, Liu CJ, Lin JW, Chen SI, Hung PH, et al. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C. Clin Infect Dis. 2010;51:541-9. [PMID: 20645865]
6. Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007;14:697-703. [PMID: 17875004]
7. Roth D, Gaynor JJ, Reddy KR, Ciancio G, Sageshima J, Kupin W, et al. Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol. 2011;22:1152-60. [PMID: 21546575]
8. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29:257-63. [PMID: 9862875]
9. Fabrizi F, Lunghi G, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients. Aliment Pharmacol Ther. 2006;24:1413-22. [PMID: 17081162]
10. Gordon CE, Uhlig K, Schmid CH, Levey AS, Wong JB. Long-term viral negativity after interferon for chronic hepatitis C virus infection in hemodialysis. Clin J Am Soc Nephrol. 2011;6:2226-34. [PMID: 21784816]
11. Huraib S, Iqbal A, Tanimu D, Abdullah A. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol. 2001;21:435-40. [PMID: 11799259]
12. Russo MW, Goldsweig CD, Jacobson IM, Brown RS Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol. 2003;98:1610-5. [PMID: 12873587]
13. Fabrizi F, Dixit V, Messa P, Martin P. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat. 2008;15:79-88. [PMID: 18184190]
14. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis. 2008;51:263-77. [PMID: 18215704]
15. Bruchfeld A, Ståhle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - a pilot study. J Viral Hepat. 2001;8:287-92. [PMID: 11454181]
16. Tan AC, Brouwer JT, Glue P, van Leusen R, Kauffmann RH, Schalm SW, et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study [Letter]. Nephrol Dial Transplant. 2001;16:193-5. [PMID: 11209032]
17. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc. 2004;36:1831-4. [PMID: 15350490]
18. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat. 2006;13:316-21. [PMID: 16637862]
19. Rendina M, Schena A, Castellaneta NM, Losito F, Amoruso AC, Stallone G, et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol. 2007;46:768-74. [PMID: 17383045]
20. Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and lowdose ribavirin. Int J Artif Organs. 2008;31:295-302. [PMID: 18432584]
21. van Leusen R, Adang RP, de Vries RA, Cnossen TT, Konings CJ, Schalm SW, et al. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant. 2008;23:721-5. [PMID: 18042614]
22. Hakim W, Sheikh S, Inayat I, Caldwell C, Smith D, Lorber M, et al. HCV response in patients with end stage renal disease treated with combination pegylated interferon alpha-2a and ribavirin. J Clin Gastroenterol. 2009;43:477-81. [PMID: 19142165]
23. Liu CH, Liang CC, Liu CJ, Tsai HB, Hung PH, Hsu SJ, et al. Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy [Letter]. Gut. 2009;58:314-6. [PMID: 19136527]
24. Deltenre P, Moreno C, Tran A, Ollivier I, Provôt F, Stanke F, et al. Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy. Aliment Pharmacol Ther. 2011;34:454-61. [PMID: 21682756]
25. Fabrizi F, Dixit V, Martin P, Messa P. Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials. J Viral Hepat. 2011;18:e263-9. [PMID: 21108701]
26. Copegus [package insert]. Nutley, NJ: Hoffmann-La Roche; 2011. Accessed at www.accessdata.fda.gov/drugsatfda-docs/label/2011/021511s023lbl.pdf on 11 August 2013.
27. Huang CF, Yeh ML, Huang JF, Yang JF, Hsieh MY, Lin ZY, et al. Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. Antiviral Res. 2012;93:239-44. [PMID: 22193282]
28. Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, et al. Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin. Antivir Ther. 2012;17:1059-67. [PMID: 22898703]
29. Liu CH, Liang CC, Liu CJ, Hsu SJ, Lin JW, Chen SI, et al. The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C. Kidney Int. 2010;78:103-9. [PMID: 20357753]
30. Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, et al. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy. Antivir Ther. 2012;17:477-84. [PMID: 22301466]
31. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139:120-9.e18. [PMID: 20399780]
32. Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology. 2008;47:1884-93. [PMID: 18508296]
33. Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis. 2008;47:1260-9. [PMID: 18834319]
34. Liu CH, Liang CC, Lin JW, Chen SI, Tsai HB, Chang CS, et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut. 2008;57:525-30. [PMID: 17881538]
35. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology. 2003;37:1351-8. [PMID: 12774014]
36. Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology. 2006;131:1040-8. [PMID: 17030174]
37. Di Martino V, Richou C, Cervoni JP, Sanchez-Tapias JM, Jensen DM, Mangia A, et al. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology. 2011;54:789-800. [PMID: 21674553]
38. Fucuta Pereira Pda S, Uehara SN, de Mello Perez R, Feldner AC, de Melo IC, de Souza e Silva IS, et al. Is early virological response as predictive of the hepatitis C treatment response in dialysis patients as in non-uremic patients? Int J Infect Dis. 2013;17:e50-3. [PMID: 23041364]
39. Gupta SK, Kantesaria B, Glue P. Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients. Eur J Clin Pharmacol. 2012;68:415-8. [PMID: 22037562]
40. Pegasys [package insert]. Nutley, NJ: Hoffmann-La Roche; 2011. Accessed at www.accessdata.fda.gov/drugsatfda-docs/label/2008/103964s5154lbl.pdf on 11 August 2013.
41. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-16. [PMID: 21696307]
42. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al; ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014-24. [PMID: 21916639]
43. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-206. [PMID: 21449783]
44. Incivek [package insert]. Cambridge, MA: Vertex Pharmaceuticals; 2013. Accessed at www.accessdata.fda.gov/drugsatfda-docs/label/2011/201917lbl.pdf on 11 August 2013.
45. Victrelis [package insert]. Whitehouse Station, NJ: Merck & Co.; 2011. Accessed at www.accessdata.fda.gov/drugsatfda-docs/label/2011/202258lbl. pdf on 11 August 2013.
46. Dumortier J, Guillaud O, Gagnieu MC, Janbon B, Juillard L, Morelon E, et al. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: Is it feasible? J Clin Virol. 2013;56:146-9. [PMID: 23149155]
47. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56:78-84. [PMID: 21827730]